JP2007532666A5 - - Google Patents

Download PDF

Info

Publication number
JP2007532666A5
JP2007532666A5 JP2007508498A JP2007508498A JP2007532666A5 JP 2007532666 A5 JP2007532666 A5 JP 2007532666A5 JP 2007508498 A JP2007508498 A JP 2007508498A JP 2007508498 A JP2007508498 A JP 2007508498A JP 2007532666 A5 JP2007532666 A5 JP 2007532666A5
Authority
JP
Japan
Prior art keywords
seq
antiviral composition
group
nuclease
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007508498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007532666A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/012532 external-priority patent/WO2005115444A2/en
Publication of JP2007532666A publication Critical patent/JP2007532666A/ja
Publication of JP2007532666A5 publication Critical patent/JP2007532666A5/ja
Pending legal-status Critical Current

Links

JP2007508498A 2004-04-14 2005-04-14 ウイルス核酸を対象とした修飾ヌクレアーゼを用いた組成物及びウイルス性疾患の予防並びに治療方法 Pending JP2007532666A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56193404P 2004-04-14 2004-04-14
PCT/US2005/012532 WO2005115444A2 (en) 2004-04-14 2005-04-14 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Publications (2)

Publication Number Publication Date
JP2007532666A JP2007532666A (ja) 2007-11-15
JP2007532666A5 true JP2007532666A5 (https=) 2008-07-03

Family

ID=35451407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007508498A Pending JP2007532666A (ja) 2004-04-14 2005-04-14 ウイルス核酸を対象とした修飾ヌクレアーゼを用いた組成物及びウイルス性疾患の予防並びに治療方法

Country Status (7)

Country Link
US (2) US9592277B2 (https=)
EP (1) EP1734991A4 (https=)
JP (1) JP2007532666A (https=)
AU (2) AU2005247298B8 (https=)
CA (1) CA2604243C (https=)
IL (1) IL178802A0 (https=)
WO (1) WO2005115444A2 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
WO2006130034A1 (fr) * 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US9592277B2 (en) * 2004-04-14 2017-03-14 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
WO2007133812A2 (en) * 2005-12-30 2007-11-22 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
EP1987055A1 (en) * 2006-02-10 2008-11-05 Dermagen AB Novel antimicrobial peptides and use thereof
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
WO2008034123A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
US8871200B2 (en) 2006-11-28 2014-10-28 Cls Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
WO2011031467A1 (en) * 2009-08-25 2011-03-17 Wayne State University Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
CA2787260A1 (en) * 2010-01-18 2011-07-21 Zhi-Min Yuan Methods and compositions for nanoparticle-mediated cancer cell-targeted delivery
KR101341640B1 (ko) * 2010-02-05 2013-12-16 한국전자통신연구원 단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
JP5794541B2 (ja) * 2010-04-21 2015-10-14 国立大学法人北海道大学 核内移行性を有する脂質膜構造体
EP2490021A1 (en) * 2011-02-18 2012-08-22 Biotempt B.V. Modulators of PRR and GPCR signalling
WO2013126872A1 (en) * 2012-02-24 2013-08-29 Wayne State University Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients
AU2013240248B2 (en) 2012-03-26 2018-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Delivery of packaged RNA to mammalian cells
CA2898184A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
WO2014197091A2 (en) * 2013-03-15 2014-12-11 Techulon Inc. Rapidly adaptable nano therapeutics for treatment of infectious disease
US11306326B2 (en) 2013-08-23 2022-04-19 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
WO2015027243A2 (en) * 2013-08-23 2015-02-26 Rutgers The State University Of New Jersey Biologically active synthetic nanoparticle constructs and mehtods of use therof
CN106232807A (zh) 2013-12-16 2016-12-14 美利坚合众国, 由健康及人类服务部部长代表 通过使用vlp复制子投递ii类mhc抗原的癌症免疫疗法
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
KR20170080579A (ko) 2014-10-01 2017-07-10 플랜트 헬스 케어, 인코포레이티드 파괴된 과민성 반응 박스를 갖는 유발제 펩티드 및 그의 용도
CA2962951A1 (en) 2014-10-01 2016-04-07 Plant Health Care, Inc. Hypersensitive response elicitor peptides and use thereof
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
CN116082457A (zh) 2016-02-01 2023-05-09 堪培拉大学 蛋白化合物及其用途
WO2019090390A1 (en) 2017-11-08 2019-05-16 University Of Canberra Immunogenic compositions and uses therefor
WO2019099685A1 (en) 2017-11-15 2019-05-23 Rutgers, The State University Of New Jersey Biodegradable hybrid inorganic nanoscaffolding materials and methods of use and manufacture thereof
CN111712468A (zh) 2017-12-22 2020-09-25 北卡罗莱纳州立大学 聚合物荧光团、包含其的组合物及制备和使用其的方法
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
EP3821003A4 (en) * 2018-07-09 2022-07-20 Gro Biosciences Inc. Non-standard amino acid containing compositions and uses thereof
WO2020106709A1 (en) * 2018-11-19 2020-05-28 Gro Biosciences Inc. Human dnase for lung disease
JP7469318B2 (ja) * 2019-01-28 2024-04-16 マイクロベンション インコーポレイテッド コーティング
US12478684B2 (en) * 2019-04-11 2025-11-25 Northeastern University Oligonucleotide-polymer miktoarm conjugates and methods of use
WO2021046307A1 (en) * 2019-09-04 2021-03-11 North Carolina State University Hybridized poly(amidoamine)-amino acid dendrimers
WO2021150867A1 (en) * 2020-01-24 2021-07-29 Sarepta Therapeutics, Inc. Designing antisense oligonucleotide delivery peptides by interpretable machine learning
WO2021231499A2 (en) * 2020-05-11 2021-11-18 Revir, Inc. Compositions and methods for treating viral infections
CA3178744C (en) 2020-05-13 2023-11-14 Ardythe L. Morrow Fucosylated oligosaccharides for prevention of coronavirus infection
WO2021231750A1 (en) * 2020-05-13 2021-11-18 Glycosyn LLC 2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation
WO2022026689A1 (en) 2020-07-30 2022-02-03 Microvention, Inc. Antimicrobial coatings
US20220040315A1 (en) 2020-08-09 2022-02-10 Fulu Labs Corporation Nuclease-dendrimer formulations for covid-19 and broad-spectrum antiviral therapy and prophylaxis
EP4203968A4 (en) * 2020-08-31 2025-07-30 Starpharma Pty Ltd DENDRIMER-DRUG CONJUGATE
CN117651550A (zh) * 2021-07-02 2024-03-05 奥古尔·米尔扎尤索夫娜·穆萨哈诺娃 用于预防SARS-CoV-2感染的药物
CN114250208B (zh) * 2021-12-22 2023-07-25 武汉瀚海新酶生物科技有限公司 耐高盐高活性DNase I突变体的制备及应用
WO2024092230A2 (en) * 2022-10-28 2024-05-02 The Regents Of The University Of California Recombinant enhanced antiviral restrictors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5115096A (en) 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein
WO1990010015A1 (en) * 1989-02-23 1990-09-07 Seragen, Inc. Chimeric toxin
US5629173A (en) * 1990-08-09 1997-05-13 Genentech, Inc. Methods of use of serine protease variants having peptide ligase activity
US5989886A (en) * 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
US5792640A (en) 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5484589A (en) 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
US5503973A (en) 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
AU7212694A (en) 1993-06-24 1995-01-17 Rufeld, Inc. Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
RU2066551C1 (ru) 1994-03-23 1996-09-20 Институт нефтехимического синтеза РАН Способ получения инсулинсодержащих полимерных гидрогелей
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5997861A (en) * 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US7432048B2 (en) * 1996-11-29 2008-10-07 Third Wave Technologies, Inc. Reactions on a solid surface
US5739512A (en) 1996-05-30 1998-04-14 Sun Microsystems, Inc. Digital delivery of receipts
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6280991B1 (en) 1997-10-15 2001-08-28 Wisconsin Alumni Research Foundation Engineered cytotoxic ribonclease
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
AU2200100A (en) 1998-12-21 2000-07-12 Genencor International, Inc. Chemically modified enzymes with multiple charged variants
US6485718B1 (en) 1999-04-13 2002-11-26 Pharmacia Corporation Site specific ligation of proteins to synthetic particles
ATE340592T1 (de) 1999-04-23 2006-10-15 Alza Corp Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US20010053521A1 (en) * 1999-09-27 2001-12-20 Kreimer David I. Amplification of analyte detection by substrates having particle structures with receptors
US6312956B1 (en) 1999-10-01 2001-11-06 Vanderbilt University Nuclear targeted peptide nucleic acid oligomer
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US7091026B2 (en) 2001-02-16 2006-08-15 University Of Iowa Research Foundation Artificial endonuclease
AU2002317437A1 (en) * 2001-05-18 2002-12-03 Cureon A/S Therapeutic uses of lna-modified oligonucleotides in infectious diseases
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
GB0126251D0 (en) * 2001-11-01 2002-01-02 Imp College Innovations Ltd Methods
BR0314236A (pt) 2002-09-13 2005-08-09 Replicor Inc Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
JP2008505853A (ja) * 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
US9592277B2 (en) * 2004-04-14 2017-03-14 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

Similar Documents

Publication Publication Date Title
JP2007532666A5 (https=)
CA2604243A1 (en) Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
Fuchs et al. Pathway for polyarginine entry into mammalian cells
KR102641844B1 (ko) 핵산 및 단백질 페이로드 전달을 위한 방법 및 조성물
TWI655204B (zh) 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
Veldhoen et al. Recent developments in peptide-based nucleic acid delivery
EP2928906B1 (en) Cell penetrating peptides for intracellular delivery of molecules
TWI598441B (zh) 穿膜胜肽以及包含該胜肽之共軛物及組成物（四）
JP5670875B2 (ja) カーゴ分子の送達ビヒクルおよび炎症反応を免疫調節するための生物学的治療剤としてのＹｏｐＭ
Wolf et al. Structural requirements for cellular uptake and antisense activity of peptide nucleic acids conjugated with various peptides
US20120171770A1 (en) Bioengineered silk protein-based nucleic acid delivery systems
WO2014053882A1 (en) Cell penetrating peptides for intracellular delivery of molecules
JP2014524738A5 (https=)
WO2014053879A1 (en) Cell penetrating peptides for intracellular delivery of molecules
JP2010508022A5 (https=)
Naik et al. Different roles of cell surface and exogenous glycosaminoglycans in controlling gene delivery by arginine-rich peptides with varied distribution of arginines
Francoia et al. Everything You Always Wanted to Know about Poly‐l‐lysine Dendrigrafts (But Were Afraid to Ask)
CN106795205A (zh) 新细胞膜穿透肽及其作为生物活性物质传递体的用途
Oehlke et al. Studies on the cellular uptake of substance P and lysine‐rich, KLA‐derived model peptides
US20040072743A1 (en) Pharmaceutical composition of modified pna molecules
CA2390104C (en) Method for transfer of molecular substances with prokaryotic nucleic acid-binding proteins
Futami et al. Design of cytotoxic ribonucleases by cationization to enhance intracellular protein delivery
Langedijk et al. New transport peptides broaden the horizon of applications for peptidic pharmaceuticals
WO2001027261A2 (en) Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino
US8722617B2 (en) Mussel adhesive protein derived vectors for gene delivery